TCT-944 Left Ventricular Outflow Tract Impact on Transcatheter Mitral Valve Interventions
Recommended Citation
Halboni A, Fram G, Giustino G, Sturla N, Engel Gonzalez P, Villablanca P, Lee J, Frisoli T, Alnajjar R, Wang D, O’Neill W, O’Neill B. TCT-944 Left Ventricular Outflow Tract Impact on Transcatheter Mitral Valve Interventions. J Am Coll Cardiol 2024; 84(18):B402.
Document Type
Conference Proceeding
Publication Date
10-29-2024
Publication Title
J Am Coll Cardiol
Abstract
Background: In patients planned for transcatheter mitral valve (MV) interventions, left ventricular outflow tract (LVOT) significantly impacts choice of therapy and outcomes. Among patients with MV disease, we studied the patterns of treatment and outcomes based on LVOT. Methods: We conducted a single-center study including all patients with severe MV disease who were evaluated by a multidisciplinary heart team for MV therapies between 2018 and 2023. All patients underwent preprocedural cardiac computed tomography as part of screening. Results: A total of 432 patients were included. One hundred fifty-seven patients (36.3%) had a predicted neo-LVOT <150 mm2, whereas 275 patients (63.7%) had a predicted neo-LVOT ≥150 mm2. The overall median predicted neo-LVOT was 304.5 mm2 (58.3-621.8). Baseline characteristics are shown in the Table. Treatment allocations are demonstrated in the Figure. Median follow-up time was 290 days (83.5-656.5). All-cause mortality in patients with a neo-LVOT <150 mm2 was 26.1% compared to 32.4% in patients with a neo LVOT ≥150 mm2 (P = 0.17). [Formula presented] [Formula presented] Conclusion: Patients with a predicted neo-LVOT <150 mm2 were older, mostly female, more likely to have severe mitral stenosis, and had fewer definitive treatment options. Strategies to address the risk of a small LVOT or innovative transcatheter MV therapies are warranted in these patients. Categories: STRUCTURAL: Valvular Disease: Mitral.
Volume
84
Issue
18
First Page
B402
